Article

A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.

Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
PLoS Medicine (Impact Factor: 14). 07/2010; 7(7):e1000307. DOI: 10.1371/journal.pmed.1000307
Source: PubMed

ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease. For patients with localized PDAC, surgery is the best option, but with a median survival of less than 2 years and a difficult and prolonged postoperative course for most, there is an urgent need to better identify patients who have the most aggressive disease.
We analyzed the gene expression profiles of primary tumors from patients with localized compared to metastatic disease and identified a six-gene signature associated with metastatic disease. We evaluated the prognostic potential of this signature in a training set of 34 patients with localized and resected PDAC and selected a cut-point associated with outcome using X-tile. We then applied this cut-point to an independent test set of 67 patients with localized and resected PDAC and found that our signature was independently predictive of survival and superior to established clinical prognostic factors such as grade, tumor size, and nodal status, with a hazard ratio of 4.1 (95% confidence interval [CI] 1.7-10.0). Patients defined to be high-risk patients by the six-gene signature had a 1-year survival rate of 55% compared to 91% in the low-risk group.
Our six-gene signature may be used to better stage PDAC patients and assist in the difficult treatment decisions of surgery and to select patients whose tumor biology may benefit most from neoadjuvant therapy. The use of this six-gene signature should be investigated in prospective patient cohorts, and if confirmed, in future PDAC clinical trials, its potential as a biomarker should be investigated. Genes in this signature, or the pathways that they fall into, may represent new therapeutic targets. Please see later in the article for the Editors' Summary.

Download full-text

Full-text

Available from: Jeran Stratford, Jul 06, 2015
0 Followers
 · 
241 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer (PC) is a leading cause of cancer related deaths in United States. The lack of early symptoms results in latestage detection and a high mortality rate. Currently, the only potentially curative approach for PC is surgical resection, which is often unsuccessful because the invasive and metastatic nature of the tumor masses makes their complete removal difficult. Consequently, patients suffer relapses from remaining cancer stem cells or drug resistance that eventually lead to death. To improve the survival rate, the early detection of PC is critical. Current biomarker research in PC indicates that a serum carbohydrate antigen, CA 19-9, is the only available biomarker with approximately 90% specificity to PC. However, the efficacy of CA 19-9 for assessing prognosis and monitoring patients with PC remains contentious. Thus, advances in technology and the detection of new biomarkers with high specificity to PC are needed to reduce the mortality rate of pancreatic cancer.
    Current pharmaceutical design 02/2012; 18(17):2439-51. DOI:10.2174/13816128112092439 · 3.29 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: a b s t r a c t Pancreatic cancer (PC) is the fourth leading cause of cancer death in the United States, with 4% survival, 5 years after diagnosis. Patients with pancreatic cancer are usually diagnosed at late stages, when the disease is incurable. Sensitive and more specific markers are critical for supporting new prevention, diagnostic or therapeutic strategies. Here, we report mass spectrometry-based metabolomic profiling of human pancreas matched tumor and normal tissue. Multivariate data analysis using two independent methods shows significant alterations in the profiles of the tumor metabolome as compared to the normal tissue. These findings offer an information-rich matrix for discovering novel candidate biomarkers with diagnostic or prognostic potential.
    International Journal of Mass Spectrometry 01/2012; 310:44-51. DOI:10.1016/j.ijms.2011.11.005 · 2.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer (PC) is the fourth leading cause of cancer death in the United States, with 4% survival 5 years after diagnosis. Patients with pancreatic cancer are usually diagnosed at late stages, when the disease is incurable. Sensitive and more specific biomarkers are thus critical for supporting new prevention, diagnostic or therapeutic strategies. Here, we report mass spectrometry-based metabolomic profiling of human pancreatic tumor and normal tissue. Multivariate data analysis shows significant alterations in the profiles of the tumor metabolome as compared to the normal. These findings offer an information-rich matrix for discovering novel biomarkers with potential for diagnostic or prognostic purposes.
    2010 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2010, Hong Kong, China, 18 - 21 December 2010, Proceedings; 01/2010